Qube Research & Technologies LTD Adagio Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	N/A	-135,081 Reduced 80.96%	31,767 $105,000
Q3 2024 Nov 14, 2024	SELL	N/A	-59,148 Reduced 26.17%	166,848 $552,000
Q2 2024 Aug 14, 2024	SELL	N/A	-86,433 Reduced 27.66%	225,996 $748,000
Q1 2024 May 14, 2024	BUY	N/A	190,623 Added 156.5%	312,429 $1.03 Million
Q4 2023 Feb 13, 2024	BUY	N/A	104,007 Added 584.34%	121,806 $403,000
Q3 2023 Nov 13, 2023	SELL	N/A	-57,731 Reduced 76.43%	17,799 $58,000
Q2 2023 Aug 14, 2023	BUY	N/A	75,530 New	75,530 $250,000

63.1M

13.9K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.